CN116731193A - Recombinant proteins and uses thereof - Google Patents
Recombinant proteins and uses thereof Download PDFInfo
- Publication number
- CN116731193A CN116731193A CN202210193357.0A CN202210193357A CN116731193A CN 116731193 A CN116731193 A CN 116731193A CN 202210193357 A CN202210193357 A CN 202210193357A CN 116731193 A CN116731193 A CN 116731193A
- Authority
- CN
- China
- Prior art keywords
- recombinant protein
- cell
- cells
- application
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 101
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 101
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 61
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 claims abstract description 19
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 65
- 239000013604 expression vector Substances 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 36
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 12
- 239000012642 immune effector Substances 0.000 claims description 11
- 229940121354 immunomodulator Drugs 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 45
- 230000028993 immune response Effects 0.000 abstract description 23
- 238000001727 in vivo Methods 0.000 abstract description 22
- 230000005764 inhibitory process Effects 0.000 abstract description 22
- 230000000259 anti-tumor effect Effects 0.000 abstract description 21
- 210000004899 c-terminal region Anatomy 0.000 abstract description 8
- 108020004414 DNA Proteins 0.000 description 24
- 102000008096 B7-H1 Antigen Human genes 0.000 description 20
- 108010074708 B7-H1 Antigen Proteins 0.000 description 20
- 229940045513 CTLA4 antagonist Drugs 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 20
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 19
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 19
- 101150036449 SIRPA gene Proteins 0.000 description 18
- 210000002865 immune cell Anatomy 0.000 description 18
- 230000003993 interaction Effects 0.000 description 18
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 17
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 17
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 17
- 102000017578 LAG3 Human genes 0.000 description 17
- 101150030213 Lag3 gene Proteins 0.000 description 17
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 17
- 230000004927 fusion Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 16
- 238000010361 transduction Methods 0.000 description 10
- 230000026683 transduction Effects 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010015666 tryptophyl-leucyl-glutamic acid Proteins 0.000 description 5
- HYPVLWGNBIYTNA-GUBZILKMSA-N Gln-Leu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HYPVLWGNBIYTNA-GUBZILKMSA-N 0.000 description 4
- LNJLOZYNZFGJMM-DEQVHRJGSA-N Ile-His-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N LNJLOZYNZFGJMM-DEQVHRJGSA-N 0.000 description 4
- PHHYNOUOUWYQRO-XIRDDKMYSA-N Lys-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N PHHYNOUOUWYQRO-XIRDDKMYSA-N 0.000 description 4
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- WOJJIRYPFAZEPF-YFKPBYRVSA-N 2-[[(2s)-2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]propanoyl]amino]acetate Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)CN WOJJIRYPFAZEPF-YFKPBYRVSA-N 0.000 description 3
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 3
- LFFOJBOTZUWINF-ZANVPECISA-N Ala-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O)=CNC2=C1 LFFOJBOTZUWINF-ZANVPECISA-N 0.000 description 3
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 3
- HICVMZCGVFKTPM-BQBZGAKWSA-N Asp-Pro-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HICVMZCGVFKTPM-BQBZGAKWSA-N 0.000 description 3
- IZJLAQMWJHCHTN-BPUTZDHNSA-N Cys-Trp-Arg Chemical compound N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O IZJLAQMWJHCHTN-BPUTZDHNSA-N 0.000 description 3
- LKUWAWGNJYJODH-KBIXCLLPSA-N Gln-Ala-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LKUWAWGNJYJODH-KBIXCLLPSA-N 0.000 description 3
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 3
- YKZAMJXNJUWFIK-JBDRJPRFSA-N Ile-Ser-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)O)N YKZAMJXNJUWFIK-JBDRJPRFSA-N 0.000 description 3
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 3
- ZRLUISBDKUWAIZ-CIUDSAMLSA-N Leu-Ala-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O ZRLUISBDKUWAIZ-CIUDSAMLSA-N 0.000 description 3
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 3
- JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MOQDPPUMFSMYOM-KKUMJFAQSA-N Ser-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CO)N MOQDPPUMFSMYOM-KKUMJFAQSA-N 0.000 description 3
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 3
- NULQKGDFWHIGMD-NYVOZVTQSA-N Trp-Cys-Trp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O NULQKGDFWHIGMD-NYVOZVTQSA-N 0.000 description 3
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 3
- OHNXAUCZVWGTLL-KKUMJFAQSA-N Tyr-His-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CS)C(=O)O)N)O OHNXAUCZVWGTLL-KKUMJFAQSA-N 0.000 description 3
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 3
- 108010008355 arginyl-glutamine Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- KQFRUSHJPKXBMB-BHDSKKPTSA-N Ala-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 KQFRUSHJPKXBMB-BHDSKKPTSA-N 0.000 description 2
- YXXPVUOMPSZURS-ZLIFDBKOSA-N Ala-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 YXXPVUOMPSZURS-ZLIFDBKOSA-N 0.000 description 2
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 2
- BOXNGMVEVOGXOJ-UBHSHLNASA-N Asp-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N BOXNGMVEVOGXOJ-UBHSHLNASA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 2
- QKWBEMCLYTYBNI-GVXVVHGQSA-N Gln-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(N)=O QKWBEMCLYTYBNI-GVXVVHGQSA-N 0.000 description 2
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 2
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 2
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 2
- CVEFOCIRMVGWDS-XIRDDKMYSA-N His-Cys-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 CVEFOCIRMVGWDS-XIRDDKMYSA-N 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- WYPVCIACUMJRIB-JYJNAYRXSA-N Phe-Gln-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N WYPVCIACUMJRIB-JYJNAYRXSA-N 0.000 description 2
- STIAINRLUUKYKM-WFBYXXMGSA-N Ser-Trp-Ala Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 STIAINRLUUKYKM-WFBYXXMGSA-N 0.000 description 2
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XXJDYWYVZBHELV-TUSQITKMSA-N Trp-Trp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCCCN)C(=O)O)N XXJDYWYVZBHELV-TUSQITKMSA-N 0.000 description 2
- MXKUGFHWYYKVDV-SZMVWBNQSA-N Trp-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(C)C)C(O)=O MXKUGFHWYYKVDV-SZMVWBNQSA-N 0.000 description 2
- KJFBXCFOPAKPTM-BZSNNMDCSA-N Val-Trp-Val Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 KJFBXCFOPAKPTM-BZSNNMDCSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 108010038745 tryptophylglycine Proteins 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- CKIBTNMWVMKAHB-RWGOJESNSA-N Ala-Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 CKIBTNMWVMKAHB-RWGOJESNSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 1
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- FBCURAVMSXNOLP-JYJNAYRXSA-N His-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N FBCURAVMSXNOLP-JYJNAYRXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- NTEVEUCLFMWSND-SRVKXCTJSA-N Lys-Arg-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O NTEVEUCLFMWSND-SRVKXCTJSA-N 0.000 description 1
- DFXQCCBKGUNYGG-GUBZILKMSA-N Lys-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN DFXQCCBKGUNYGG-GUBZILKMSA-N 0.000 description 1
- XBAJINCXDBTJRH-WDSOQIARSA-N Lys-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N XBAJINCXDBTJRH-WDSOQIARSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- VOAKKHOIAFKOQZ-JYJNAYRXSA-N Met-Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)CC1=CC=C(O)C=C1 VOAKKHOIAFKOQZ-JYJNAYRXSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241001477931 Mythimna unipuncta Species 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- XSXABUHLKPUVLX-JYJNAYRXSA-N Pro-Ser-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O XSXABUHLKPUVLX-JYJNAYRXSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- RTXKJFWHEBTABY-IHPCNDPISA-N Ser-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CO)N RTXKJFWHEBTABY-IHPCNDPISA-N 0.000 description 1
- HAUVENOGHPECML-BPUTZDHNSA-N Ser-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 HAUVENOGHPECML-BPUTZDHNSA-N 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
- VPRHDRKAPYZMHL-SZMVWBNQSA-N Trp-Leu-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 VPRHDRKAPYZMHL-SZMVWBNQSA-N 0.000 description 1
- UPNRACRNHISCAF-SZMVWBNQSA-N Trp-Lys-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 UPNRACRNHISCAF-SZMVWBNQSA-N 0.000 description 1
- WANVRBAZGSICCP-SRVKXCTJSA-N Val-Pro-Met Chemical compound CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C)C(O)=O WANVRBAZGSICCP-SRVKXCTJSA-N 0.000 description 1
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000008889 homeostatic pathway Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- -1 recombinant cells Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application provides a recombinant protein and application thereof, wherein the recombinant protein comprises: at least one of the following: d4-2, C25, TPP-1, PPL-C and ERY2-4, the C-terminal of D4-2 with the N end of C25 links to each other, the C-terminal of C25 with the N end of TPP-1 links to each other, the C-terminal of TPP-1 with the N end of PPL-C links to each other, the C-terminal of PPL-C with the N end of ERY2-4. The recombinant protein prepared by the application can effectively solve the problem of immune response inhibition, has longer half-life in vivo compared with short peptide, can effectively treat or prevent cancers, and remarkably improves the anti-tumor effect.
Description
Technical Field
The application belongs to the field of biological medicine, in particular to recombinant protein and application thereof, and more particularly relates to recombinant protein, nucleic acid molecules, expression vectors, recombinant cells, compositions, application of the recombinant protein, the nucleic acid molecules, the expression vectors, the recombinant cells or the compositions in preparation of medicines and the medicines.
Background
Immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1/PD-L1, anti-LAG-3, anti-CD 47/sirpa) target the natural immune homeostatic pathway to drive a stronger immune response against tumors, have become a treatment strategy for advanced tumors, and blockade of immune checkpoints will overcome immune tolerance in the tumor microenvironment and enhance anti-tumor immunity, inducing continued tumor remission. Thus blocking inhibitory signals, reactivating immune function has become an effective means for treating cancer, and in 2011, the us FDA approved CTLA-4 antibodies for treatment of melanoma, and in 2014 approved PD-1 antibodies for treatment of melanoma and other cancers. Although immune blocking therapy has the advantages of strong specificity and high stability, long-term injection therapy is easy to induce the organism to generate anti-antibody and complement-mediated cytotoxicity: ADCC (antibody dependent cell mediated cytotoxicity) and CDC (complement dependent cytotoxicity) effects, whose discrete toxicities caused by nonspecific activation of the immune system cause the appearance of inflammatory symptoms in the corresponding organs, known as immune-related adverse reactions (immune-related adverse events, irAEs), which can involve multiple systems, multiple organs, occur at irregular times, during treatment or at any time after cessation of treatment, are important for the safe use of immune checkpoint inhibitors.
In addition, there are also a number of immunosuppressive mechanisms in the tumor microenvironment that even blocking the PD-L1, CTLA-4 pathways is insufficient to restore the immune system. Although PD-1 or PD-L1 antibodies alter the pattern of many advanced cancer patients, including melanoma, lung cancer, breast cancer, renal cancer, etc., good long-term results are achieved. However, is effective in only a fraction of patients and may produce toxic effects. Meanwhile, gene therapy is a potential effective method for treating genetic diseases, but factors such as the size, charge and stability of oligonucleotide and plasmid DNA for gene therapy cannot be effectively absorbed by cells, and the curative effect is seriously affected. Thus, there remains a need to further develop products directed against tumor immunosuppression.
Disclosure of Invention
The present application aims to solve, at least to some extent, one of the above technical problems or to at least provide a commercial choice.
In the application, the inventor designs a plurality of exogenous injection proteins aiming at tumor models, and obtains dominant recombinant proteins after a large number of experimental screening, the recombinant proteins can effectively solve the problems of immune response inhibition and the like, and have the characteristic of longer half-life in vivo compared with short peptides. Furthermore, the inventor loads the genome encoding the recombinant protein into a tumor specific T cell, and the T cell continuously expresses and secretes immune checkpoint inhibitory short peptide in tumor tissues, so that the problem of insufficient tissue penetration caused by short peptide injection is effectively avoided, the activation of the whole immune system is avoided, and the recombinant protein has very important benefit to tumor patients.
Thus, in a first aspect of the application, the application proposes a recombinant protein. According to an embodiment of the application, at least two of the following are included: d4-2, C25, TPP-1, PPL-C and ERY2-4. The inventor performs recombination and screening on various immune checkpoint inhibitory peptides through a large number of experiments to obtain various dominant recombinant proteins, and the recombinant proteins according to the embodiment of the application can effectively block the interaction between tumor cells expressing immune checkpoints and immune cells, can effectively solve the problem of immune response inhibition, and have longer in vivo half-life compared with short peptides, can effectively treat or prevent cancers, and can remarkably improve the anti-tumor effect.
In a second aspect of the application, the application provides a nucleic acid. According to an embodiment of the application, the nucleic acid encodes the recombinant protein of the first aspect. The recombinant protein coded by the nucleic acid can effectively block the interaction between tumor cells expressing immune check points PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, can effectively solve the problem of immune response inhibition, has longer in vivo half-life compared with short peptides, can effectively treat or prevent cancers, and has obviously improved anti-tumor effect.
In a third aspect of the application, the application provides an expression vector. According to an embodiment of the application, the expression vector comprises: the nucleic acid molecule of the second aspect. The expression vector may include optional control sequences operably linked to the nucleic acid molecule. Wherein the control sequences are one or more control sequences that direct expression of the nucleic acid molecule in a host, which control sequences may be derived directly from the vector itself or may be exogenous, i.e., not derived from the vector itself. The expression vector provided by the embodiment of the application can efficiently express the recombinant protein in a proper host cell, the recombinant protein can effectively block the interaction between tumor cells expressing immune check points PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, the problem of immune response inhibition can be effectively solved, and compared with a short peptide, the recombinant protein has longer half-life in vivo, can effectively treat or prevent cancers, and has obviously improved anti-tumor effect.
In a fourth aspect of the application, the application provides a method for preparing the recombinant protein according to the first aspect. According to an embodiment of the application, it comprises: introducing the expression vector of the third aspect into a cell; the cells are cultured under conditions suitable for protein expression and secretion to obtain the recombinant protein. The recombinant protein obtained by the method provided by the embodiment of the application can effectively block the interaction between tumor cells expressing immune check points PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, can effectively solve the problem of immune response inhibition, has longer in vivo half-life compared with short peptides, can effectively treat or prevent cancers, and has obviously improved anti-tumor effect.
In a fifth aspect of the application, the application provides a recombinant cell. According to an embodiment of the application, the recombinant cell carries a nucleic acid according to the second aspect, an expression vector according to the third aspect or expresses a recombinant protein according to the first aspect. The recombinant protein obtained by expressing and secreting the recombinant cells provided by the embodiment of the application under a certain condition can effectively block the interaction between tumor cells expressing immune check points PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, can effectively solve the problem of immune response inhibition, has longer half-life in vivo compared with immune check point inhibition short peptides, can effectively treat or prevent cancers, and has obviously improved anti-tumor effect.
In a sixth aspect of the application, the application provides a composition. According to an embodiment of the application, it comprises: the recombinant protein of the first aspect, the nucleic acid of the second aspect, the expression vector of the third aspect, or the recombinant cell of the fifth aspect. As described above, the recombinant protein according to the embodiment of the application can effectively block the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, can effectively solve the problem of immune response inhibition, and has longer in vivo half-life compared with immune checkpoint inhibition short peptides, so that the composition containing the recombinant protein, such as food composition, pharmaceutical composition and the like, can also effectively solve the problem of immune response inhibition, has longer effective time in vivo, can effectively treat or prevent cancers, has remarkable effect of treating or preventing tumors, and has higher safety and smaller side effect.
In a seventh aspect of the application, the application provides the use of a recombinant protein according to the first aspect, a nucleic acid according to the second aspect, an expression vector according to the third aspect, a recombinant cell according to the fifth aspect or a composition according to the sixth aspect for the preparation of a medicament. According to an embodiment of the application, the medicament is for the treatment or prevention of cancer. According to the recombinant protein, the recombinant protein obtained by using nucleic acid, an expression vector and recombinant cells or part of protein in the composition, provided by the embodiment of the application, the interaction between tumor cells expressing immune check points PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells can be effectively blocked under a certain condition, the problem of immune response inhibition can be effectively solved, and compared with short peptides, the recombinant protein has a longer in vivo half-life, can effectively treat or prevent cancers, and has a significantly improved anti-tumor effect.
In an eighth aspect of the application, the application provides a medicament. According to an embodiment of the application, the medicament comprises: the recombinant protein of the first aspect, the nucleic acid of the second aspect, the expression vector of the third aspect, the recombinant cell of the fifth aspect, or the composition of the sixth aspect. As described above, the recombinant protein of the embodiment of the application can effectively block the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, so that the problem of immune response inhibition can be solved, and compared with a short peptide, the recombinant protein has longer in vivo half-life, so that the medicament containing the recombinant protein and a series of related substances has obvious effect of treating or preventing cancers.
In a ninth aspect of the application, the application provides an immune effector cell. According to an embodiment of the application, the immune effector cell carries the nucleic acid molecule, expression vector or expresses the recombinant protein as described above. According to the specific embodiment of the application, the effector cells have tumor specificity, the T cells can continuously express and secrete immune checkpoint inhibitory peptide in tumor tissues, the problem of insufficient tissue penetration caused by peptide injection is effectively avoided, the effector cells are only expressed on the surfaces of the tumor cells, the activation of the whole immune system is avoided, the anti-tumor effect is obvious, the safety is high, and the side effect is small.
In a tenth aspect of the application, the application provides a method of treating or preventing cancer. According to an embodiment of the application, the method comprises administering to the subject a recombinant protein, expression vector, recombinant cell, immune effector cell, composition or medicament as previously described. As described above, the recombinant protein of the embodiment of the application can effectively block the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, so that the problem of immune response inhibition can be solved, and compared with a short peptide, the recombinant protein has longer in vivo half-life, therefore, the recombinant protein and a series of substances related to the recombinant protein are given to a subject, and the recombinant protein has obvious effect of treating or preventing cancers.
Additional aspects and advantages of the application will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the application.
Drawings
The foregoing and/or additional aspects and advantages of the application will become apparent and may be better understood from the following description of embodiments taken in conjunction with the accompanying drawings in which:
FIG. 1 is a schematic diagram of recombinant protein Blockine and Fusion-Blockine structures according to an embodiment of the application, wherein n represents an nth immune checkpoint inhibitory peptide, and n is a positive integer;
FIG. 2 is a graph of the efficiency results of identifying Blockine, fusion-Blockine to OT-1T cell engineering by flow through EGFP expression in accordance with an embodiment of the present application;
FIG. 3 is a graph of the results of identifying secreted and expressed Block-4 of OT-1T cells by Dot-blot against an HA tag according to an embodiment of the present application;
FIG. 4 is a graph showing the detection results of the proteins Block 1-6 and Fusion-Block on tumor growth in a tumor mouse model according to an embodiment of the present application, wherein Control represents a Control group; and
FIG. 5 is a graph showing the results of detection of tumor growth in a tumor mouse model by recombinant proteins Fusion-block-S, fusion-block-1-4 according to an embodiment of the present application, wherein Control represents a Control group.
Detailed Description
Reference will now be made in detail to embodiments of the present application, examples of which are illustrated in the accompanying drawings. The embodiments described below by referring to the drawings are illustrative and intended to explain the present application and should not be construed as limiting the application.
Furthermore, the terms "first," "second," and the like, are used for descriptive purposes only and are not to be construed as indicating or implying a relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defining "a first" or "a second" may explicitly or implicitly include at least one such feature. In the description of the present application, the meaning of "plurality" means at least two, for example, two, three, etc., unless specifically defined otherwise.
"operably linked" herein refers to the linkage of a foreign gene to a vector such that control elements within the vector, such as transcription control sequences and translation control sequences, and the like, are capable of performing their intended functions of regulating transcription and translation of the foreign gene.
The endpoints and any values of the ranges disclosed herein are not limited to the precise range or value, and are understood to encompass values approaching those ranges or values. For numerical ranges, one or more new numerical ranges may be found between the endpoints of each range, between the endpoint of each range and the individual point value, and between the individual point value, in combination with each other, and are to be considered as specifically disclosed herein.
In order that the application may be more readily understood, certain technical and scientific terms are defined below. Unless clearly defined otherwise herein in this document, all other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The abbreviations for amino acid residues are standard 3-letter and/or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids.
In a first aspect of the application, the application provides a recombinant protein comprising at least two of the following: d4-2, C25, TPP-1, PPL-C and ERY2-4. The inventor performs recombination and screening on various immune checkpoint inhibitory peptides through a large number of experiments to obtain various dominant recombinant proteins, the recombinant proteins can effectively solve the problem of immune response inhibition, and compared with short peptides, the recombinant proteins have longer half-life in vivo, can effectively treat or prevent cancers, and remarkably improve the anti-tumor effect.
According to some embodiments of the application, the recombinant protein may further include at least one of the following additional technical features:
according to some embodiments of the application, the recombinant proteins include D4-2, C25, TPP-1, PPL-C and ERY2-4.
According to some embodiments of the application, the C-terminal of D4-2 is connected to the N-terminal of C25, the C-terminal of C25 is connected to the N-terminal of TPP-1, the C-terminal of TPP-1 is connected to the N-terminal of PPL-C, and the C-terminal of PPL-C is connected to the N-terminal of ERY2-4. The inventor carries out recombination and screening on various immune checkpoint inhibitory peptides through a large number of experiments to obtain various dominant recombinant proteins, wherein when the C end of D4-2 is connected with the N end of C25, the C end of C25 is connected with the N end of TPP-1, the C end of TPP-1 is connected with the N end of PPL-C, and the C end of PPL-C is connected with the N end of ERY2-4, the obtained recombinant proteins can effectively block the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, can effectively solve the problem of immune response inhibition, and compared with the single short peptides D4-2, C25, TPP-1, PPL-C or ERY2-4, the obtained recombinant proteins have longer half-life in vivo, can effectively treat or prevent cancers, and can obtain extremely remarkable anti-tumor effects.
According to some embodiments of the application, the amino acid sequence shown as SEQ ID NO. 30, or an amino acid sequence having at least 95%, 90%, 85% identity to the amino acid sequence shown as SEQ ID NO. 25, is included.
Fusion-block S has the amino acid sequence shown below:
YASYHCWCWRDPGRSAAWGQAILEGELAWLEGGGGGAGQLADLKRQLAWWKQAAKDWSISARYSAVYSIHPSWAVPMTYRAAVSVSHFQKVWVV(SEQ ID NO:30)。
in a second aspect of the application, the application provides a nucleic acid encoding the recombinant protein of the first aspect. According to the nucleic acid-encoded recombinant protein provided by some specific embodiments of the application, the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells can be effectively blocked, the problem of immune response inhibition can be effectively solved, compared with a short peptide, the nucleic acid-encoded recombinant protein has a longer in vivo half-life period, can effectively treat or prevent cancers, and the anti-tumor effect is remarkably improved.
According to some embodiments of the application, the nucleic acid may further comprise at least one of the following additional technical features:
according to some embodiments of the application, the nucleic acid has the sequence of SEQ ID NO:8, and a nucleotide sequence shown in SEQ ID NO.
The gene encoding Fusion-block S has the nucleotide sequence shown below:
AAGGACTGGAGTATAAGCGCCCGATACTCCGCAGTATACAGTATCCATCCCTCATGGCAGTTCCAATGACCTATCGCGCCGCATACGCCAGCTACCACTGCTGGTGCTGGAGGGACCCCGGCAGGAGCGTCTCCGTGAGCCACTTCCAGAAGGTGTGGGGCAGCCTGGGGGCAGGCCATATTGGAAGGCGAGCTTGCATGGCTGGAGGGCGGGGGCGGCGGTGCTGGCCAACTGGCCGACCTGAAACGGCAGCTTGCTTGGTGGAAGCAAGCTGCA(SEQ ID NO:8)。
it should be noted that, for the nucleic acids mentioned in the present specification and claims, one skilled in the art will understand that either one or both of the complementary double strands are actually included. For convenience, in the present description and claims, although only one strand is shown in most cases, the other strand complementary thereto is actually disclosed. In addition, the nucleic acid sequences of the present application include DNA forms or RNA forms, one of which is disclosed, meaning the other is also disclosed.
In a third aspect of the present application, the present application provides an expression vector comprising: the nucleic acid molecule of the second aspect. The expression vector may include optional control sequences operably linked to the nucleic acid molecule. Wherein the control sequences are one or more control sequences that direct expression of the nucleic acid molecule in a host, which control sequences may be derived directly from the vector itself or may be exogenous, i.e., not derived from the vector itself. The expression vector provided by some specific embodiments of the application can efficiently express the recombinant protein in a proper host cell, the recombinant protein can effectively block the interaction between tumor cells expressing immune check points PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, the problem of immune response inhibition can be effectively solved, and compared with short peptides, the recombinant protein has longer in vivo half-life, can effectively treat or prevent cancers, and has obviously improved anti-tumor effect.
In a fourth aspect of the application, the application provides a method for preparing a recombinant protein according to the first aspect, comprising: introducing the expression vector of the third aspect into a cell; the cells are cultured under conditions suitable for protein expression and secretion to obtain the recombinant protein. The recombinant protein obtained by the method according to some specific embodiments of the application can effectively block the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, can effectively solve the problem of immune response inhibition, has longer half-life in vivo compared with short peptides, can effectively treat or prevent cancers, and has obviously improved anti-tumor effect.
According to some embodiments of the application, the method may further comprise at least one of the following additional technical features:
according to some embodiments of the application, the cell is a eukaryotic cell.
According to some embodiments of the application, the eukaryotic cell is a mammalian cell.
According to some embodiments of the application, the mammalian cell comprises at least one selected from CHO-K1, CHOs, 293F, 293T, CAR-T, TCR-T, TIL, CAR-NK, CAR-M and CAR-DC.
According to some embodiments of the application, the mammalian cells do not include animal germ cells, fertilized eggs, or embryonic stem cells.
In a fifth aspect of the application, the application provides a recombinant cell carrying a nucleic acid according to the second aspect, or an expression vector according to the third aspect. The recombinant protein secreted by the recombinant cells according to some specific embodiments of the application can effectively block the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, can effectively solve the problem of immune response inhibition, has longer in vivo half-life compared with short peptides, can effectively treat or prevent cancers, and has obviously improved anti-tumor effect.
It should be noted that the recombinant cells of the present application are not particularly limited, and may be prokaryotic cells, eukaryotic cells, or phage. The prokaryotic cell can be escherichia coli, bacillus subtilis, streptomycete or proteus mirabilis and the like. The eukaryotic cells can be fungi such as pichia pastoris, saccharomyces cerevisiae, schizosaccharomyces, trichoderma and the like, insect cells such as armyworm and the like, plant cells such as tobacco and the like, and mammalian cells such as BHK cells, CHO cells, COS cells, myeloma cells and the like. In some embodiments, the recombinant cells of the application are preferably mammalian cells, including T cells, BHK cells, CHO cells, NSO cells, or COS cells, and do not include animal germ cells, fertilized eggs, or embryonic stem cells.
The term "suitable conditions" as used herein refers to conditions suitable for expression of the recombinant protein of the present application. Those skilled in the art will readily appreciate that conditions suitable for expression of the recombinant protein include, but are not limited to, suitable transformation or transfection means, suitable transformation or transfection conditions, healthy host cell status, suitable host cell density, suitable cell culture environment, suitable cell culture time. The "suitable conditions" are not particularly limited, and those skilled in the art can optimize the conditions for optimal expression of the recombinant protein according to the specific environment of the laboratory.
In a sixth aspect of the application, the application provides a composition comprising: the recombinant protein of the first aspect, the nucleic acid of the second aspect, the expression vector of the third aspect, or the recombinant cell of the fifth aspect. As described above, the recombinant protein according to some embodiments of the present application can effectively block the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, and thus, the composition comprising the recombinant protein, such as food composition, pharmaceutical composition, etc., can effectively solve the problem of immune response inhibition as well, and has longer effective duration in vivo, can effectively treat or prevent cancer, has remarkable tumor treatment or prevention effect, and has higher safety and less side effects.
It is noted that the compositions include combinations that are separated in time and/or space, so long as they are capable of co-acting to achieve the objects of the present application. For example, the ingredients contained in the composition may be administered to the subject in whole or separately. When the components contained in the composition are separately administered to a subject, the individual components may be administered to the subject simultaneously or sequentially.
In a seventh aspect, the application provides the use of a recombinant protein according to the first aspect, a nucleic acid according to the second aspect, an expression vector according to the third aspect, a recombinant cell according to the fifth aspect or a composition according to the sixth aspect for the preparation of a medicament for the treatment or prevention of cancer. According to the recombinant protein, the recombinant protein obtained by using nucleic acid, an expression vector and recombinant cells or part of protein in a composition of some specific embodiments of the application, the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells can be effectively blocked under certain conditions, so that the problem of immune response inhibition is effectively solved, and compared with a short peptide, the recombinant protein has a longer in vivo half-life, can effectively treat or prevent cancers, and has a remarkably improved anti-tumor effect.
According to some embodiments of the present application, the above-mentioned medicament may further comprise at least one of the following additional technical features:
according to some embodiments of the application, the cancer comprises at least one of: gastric cancer, intestinal cancer, head and neck cancer, melanoma.
In an eighth aspect of the application, the application provides a medicament comprising: the recombinant protein of the first aspect, the nucleic acid of the second aspect, the expression vector of the third aspect, the recombinant cell of the fifth aspect, or the composition of the sixth aspect. As described above, the recombinant protein of the embodiment of the application can effectively block the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, so that the problem of immune response inhibition can be solved, and compared with a short peptide, the recombinant protein has longer in vivo half-life, so that the medicament containing a series of substances related to the recombinant protein has obvious effect of treating or preventing cancers.
According to some embodiments of the present application, the above-mentioned medicament may further comprise at least one of the following additional technical features:
according to some embodiments of the application, the cancer comprises at least one of: gastric cancer, intestinal cancer, head and neck cancer, melanoma.
According to some embodiments of the present application, there is provided a medicament comprising a pharmaceutically acceptable carrier and an effective amount of an active ingredient of the recombinant protein.
As used herein, the term "effective amount" or "effective dose" refers to an amount that is functional or active in and acceptable to a human and/or animal.
As used herein, a "pharmaceutically acceptable" ingredient is a substance that is suitable for use in humans and/or mammals without undue adverse side effects (such as toxicity, irritation, and allergic response), commensurate with a reasonable benefit/risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents.
The medicament of the application contains safe and effective amount of the active ingredients of the application and pharmaceutically acceptable carriers. Such vectors include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. Generally, the pharmaceutical preparation is matched with the administration mode, and the dosage forms of the medicine are injection, oral preparation (tablet, capsule and oral liquid), transdermal agent and sustained release agent. For example, by using physiological saline or an aqueous solution containing glucose and other auxiliary agents by conventional methods. The medicament is preferably manufactured under aseptic conditions.
The effective amount of the active ingredient described herein may vary depending upon the mode of administration, the severity of the condition being treated, and the like. The selection of the preferred effective amount can be determined by one of ordinary skill in the art based on a variety of factors (e.g., by clinical trials). Such factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life etc.; the severity of the disease to be treated in the patient, the weight of the patient, the immune status of the patient, the route of administration, etc. For example, separate doses may be administered several times per day, or the dose may be proportionally reduced, as dictated by the urgent need for the treatment of the condition.
Pharmaceutically acceptable carriers described herein include (but are not limited to): water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, nanogels, or combinations thereof. The choice of carrier should be compatible with the mode of administration and will be well known to those of ordinary skill in the art.
In a ninth aspect of the application, the application provides an immune effector cell carrying a nucleic acid molecule, expression vector or recombinant protein as described hereinbefore. According to the specific embodiment of the application, the immune effector cells have tumor specificity, the T cells can continuously express and secrete immune checkpoint inhibitory peptide in tumor tissues, the problem of insufficient tissue penetration caused by peptide injection is effectively avoided, the expression is only carried out on the surfaces of the tumor cells, the activation of the whole immune system is avoided, the anti-tumor effect is obvious, the safety is high, and the side effect is small.
In a tenth aspect of the application, the application provides a method of treating or preventing cancer comprising administering to a subject a recombinant protein, expression vector, recombinant cell, immune effector cell, composition or medicament as described previously. As described above, the recombinant protein according to some embodiments of the present application can effectively block the interaction between tumor cells expressing immune checkpoints PD-1/PD-L1, LAG-3, CTLA-4 or CD47/SIRP alpha and immune cells, thereby solving the problem of immune response inhibition, and has a longer in vivo half-life than a short peptide, so that the recombinant protein and a series of substances related thereto are administered to a subject, and also have a remarkable effect of treating or preventing cancer.
The embodiments will be described in detail below. The examples are not to be construed as limiting the specific techniques or conditions described in the literature in this field or as per the specifications of the product. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
EXAMPLE 1 construction of expression vectors
In this embodiment, expression vectors of Blockine and Fusion-Blockine are constructed, and specific experimental operation steps are as follows:
construction of expression vectors
1.1 obtaining immune checkpoint inhibitory peptides
The inventor obtains nucleotide sequences encoding immune checkpoint inhibitory peptides D4-2 (Block 1), C25 (Block 2), TPP-1 (Block 3), PPL-C (Block 4) and ERY2-4 (Block 5) by a chemical synthesis method, and constructs nucleotide fragments encoding recombinant protein Fusion Block by using the nucleotide sequences, wherein the nucleotide sequences are respectively as follows: fusion Blockine S (D4-2) - (C25) - (TPP-1) - (PPL-C) - (ERY 2-4); fusion Block 1 (TPP-1) - (ERY-2) - (D4-2) - (C25) - (PPL-C); fusion Block 2 (PPL-C) - (D4-2) - (ERY 2-4) - (C25); fusion Block ine3 (TPP-1) - (D4-2) - (ERY 2-4) - (PPL-C) - (C25); fusion Block 4 (C25) - (TPP-1) - (ERY 2-4) - (D4-2) - (PPL-C), the specific nucleotide sequences of which are shown in Table 1.
Table 1:
in addition, the inventors obtained nucleotide sequences encoding human or mouse IL-2 secretion signal peptide (SEQ ID NO: 6) and HA (hemagglutinin) (SEQ ID NO: 7) tags by a chemical synthesis method, and linked the nucleotide sequences encoding the signal peptide and the tag, respectively, as shown in Table 2:
table 2:
the nucleotide sequence codes shown in Table 2 obtain the structure of a block and Fusion block precursor protein shown in figure 1, wherein the N end of the block and Fusion block precursor protein is connected with an IL-2 signal peptide, the C end of the block and Fusion block precursor protein is connected with an HA tag, the signal peptide helps to locate the block and Fusion block protein, and the signal peptide is hydrolyzed and separated after the protein is mature, so that the finally obtained block and Fusion block protein does not contain the IL-2 signal peptide.
1.2 construction of expression vectors
The nucleotide sequences of block and Fusion-block obtained in Table 2 of step 1.1, carrying the IL-2 signal peptide and the detection tag HA, were ligated into the expression retroviral vector by homologous recombination using BamH-1 cleavage, respectively (Addgene, # 12282). The obtained cloning vector was sequenced and the sequencing results were consistent with expectations.
Example 2 preparation of recombinant proteins
Isolation and purification of CD8 from spleen and lymph node tissues of OT-I transgenic mice + T lymphocytes and activated, and viral transduction was performed 24 hours after activation; after 6 hours, the culture medium containing 20U/mL IL-2 needs to be replaced for continuous culture, and after 12 hours, transduction is performed again, 4 times of virus transduction are performed in total, and 3 times of culture medium containing 20U/mL IL-2 needs to be replaced in the period of time, so that the transduction efficiency is improved. After a further 24 hours of culture with a new medium, the engineered T cells were isolated using flow sorting. The specific operation steps of the T cell separation, activation and virus transduction flow are as follows:
(1) Packaging the retrovirus: the plasmid obtained in example 1 was transfected into Plat-E cells of a retrovirus packaging cell line using PEI, cultured using RPMI-1640 medium (350-000-CL), and virus supernatants were collected after 48 and 72 hours;
(2) Isolation and transduction of T cells: tumor-specific T cells were cultured by pre-plating 3-5 μg/mL anti-mouse-CD3 epsilon antibody in 6 well plates, diluting with 1 x dpbs, adding 1mL per well, incubating in 37 ℃ cell incubator for 1-3h or overnight at 4 ℃, and gently washing with 1 x dpbs once after completion. Isolation of CD8 from spleen and lymph node tissues of OT-I mice using MojoSort CD8 negative selection (Biolegend) magnetic bead sorting kit + T cells, plated in 6 well plates, 2 mL/well T cell medium, 1 x 10 6 -2*10 7 Per well OT-I T cells, 2. Mu.g/mL anti-mouse-CD28 antibody and 20U/mL IL-2 cytokine were added for 24h activation.
(3) After activation of anti-tumor OT-I T cells, the virus liquid supernatants (6 mL/well) packed with individual short peptides and fusion short peptides were transduced into 1mL OT-I T cells (1 x 10) 6 -2*10 7 cells), 10mM HEPES, 500uL FBS, 8. Mu.g/mL Polybrene were added, and after centrifugation at 1200g at 32℃for 90min, the culture was continued overnight, and after 6 hours the medium containing 20U/mL IL-2 cytokine was replaced, and after 12 hours secondary viral transduction was performed. A total of 4 viral transduction were performed.
(4) EGFP detection by Flow cytometry after 24h + The positive rate, i.e. the transduction efficiency was measured, and the specific experimental results are shown in fig. 2.
(5) Detecting the secretory expression of the target short peptide outside the T cells: t cells successfully transduced are sorted by using a flow sorting technology (transduction efficiency is more than 63.3% and is optimal, EGFP is obtained + Shown in fig. 2); culturing T cells selected by nutrients, collecting culture supernatant after 24 hours, and verifying secretion effect of the Blockine by using Dot-blot experiment, wherein the Dot-blot experiment result of the Blockine-4 protein is taken as an example, and the result is shown in figure 3; wherein the amino acid sequence of each protein obtained is as follows:
immune checkpoint inhibitory peptide Blockine1 (D4-2) comprises the following amino acid sequence:
KDWSISARYSAVYSIHPSW(SEQ ID NO:23)。
immune checkpoint inhibitory peptide Blockine2 (C25) comprises the amino acid sequence:
AVPMTYRAA(SEQ ID NO:24)。
immune checkpoint inhibitory peptide Blockine3 (TPP-1) comprises the following amino acid sequence:
YASYHCWCWRDPGRS(SEQ ID NO:25)。
immune checkpoint inhibitory peptide Blockine4 (PPL-C) includes the following amino acid sequences:
VSVSHFQKVWVV(SEQ ID NO:26)。
immune checkpoint inhibitory peptide Blockine5 (ERY 2-4) comprises the following amino acid sequence:
AAWGQAILEGELAWLEGGGGGAGQLADLKRQLAWWKQAA(SEQ ID NO:27)。
the human or mouse IL-2 secretion signal peptide comprises the following amino acid sequence:
MYRMQLLSCIALSLALVTNS(SEQ ID NO:28)。
HA comprises the following amino acid sequence:
YPYDVPDYA(SEQ ID NO:29)。
fusion Blockine S comprises the amino acid sequence shown below:
YASYHCWCWRDPGRSAAWGQAILEGELAWLEGGGGGAGQLADLKRQLAWWKQAAKDWSISARYSAVYSIHPSWAVPMTYRAAVSVSHFQKVWVV(SEQ ID NO:30)。
fusion block 1 comprises the amino acid sequence shown below:
VSVSHFQKVWVVKDWSISARYSAVYSIHPSWYASYHCWCWRDPGRSAAWGQAILEGELAWLEGGGGGAGQLADLKRQLAWWKQAAAVPMTYRAA(SEQ ID NO:31)。
fusion block 2 comprises the amino acid sequence shown below:
YASYHCWCWRDPGRSKDWSISARYSAVYSIHPSWAAWGQAILEGELAWLEGGGGGAGQLADLKRQLAWWKQAAVSVSHFQKVWVVAVPMTYRAA(SEQ ID NO:32)。
fusion block 3 comprises the amino acid sequence shown below:
AVPMTYRAAYASYHCWCWRDPGRSAAWGQAILEGELAWLEGGGGGAGQLADLKRQLAWWKQAAKDWSISARYSAVYSIHPSWVSVSHFQKVWVV(SEQ ID NO:33)。
fusion block 4 comprises the amino acid sequence shown below:
KDWSISARYSAVYSIHPSWAVPMTYRAAYASYHCWCWRDPGRSVSVSHFQKVWVVAAWGQAILEGELAWLEGGGGGAGQLADLKRQLAWWKQAA(SEQ ID NO:34)。
example 3 evaluation of anti-tumor Effect of recombinant proteins
In this example, the recombinant proteins Block-1, 2, 3, 4, 5, fusion-Block-S and Fusion-Block-1-4 obtained in example 2 were tested for their antitumor ability, and specific experimental procedures were as follows:
(1) Construction of tumor-bearing mouse model
The inventors constructed a melanoma tumor model by inoculating 50, 6-week-old male C57BL/6 mice with melanoma (B16F 10-Ova) cells (2X 10) 5 /v), tumor formation after 12 d.
(2) Tumor model mouse treatment
Control and experimental groups were set up and the OT-1EGFP obtained in example 2 was purified using flow cytometry + After positive cells are sorted, the positive cells are infused back into a melanin tumor model body through orbital intravenous injection, and the infusion quantity is 2 x 10 5 -5*10 5 /only. Wherein, the control group was given T cells not transduced and expressing short peptide (i.e., T cells transduced with empty plasmid used in example 1) to the tumor mice respectively for adoptive feedback, the experimental group was given T cells transduced and expressing short peptide or fusion short peptide to the tumor mice respectively for adoptive feedback, and the mice after adoptive feedback were fed for 14 days, and tumor size and body weight of the mice were measured every three days after treatment, thereby evaluating the antitumor effect of the secretory immune checkpoint inhibitory peptide. When the tumor size is not more than 1000mm 3 At this time, tumor-infiltrating lymphocytes were isolated and analyzed for changes in tumor microenvironment.
(3) Treatment effect monitoring
Specific experimental results are shown in fig. 4 and 5, wherein fig. 4 shows that at day 14, all of block-1, 2, 3, 4, 5 and Fusion-block-1 can effectively slow down the growth of mouse tumor, and the effect of Fusion-block-1 is most remarkable, and block-5 (block-PPLC) times. FIG. 5 shows that Fusion-Block-1, 2, 3, 4, S was effective in slowing down tumor growth in mice at day 14, wherein Fusion-Block-S showed more excellent anti-tumor effects.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present application. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, the different embodiments or examples described in this specification and the features of the different embodiments or examples may be combined and combined by those skilled in the art without contradiction.
While embodiments of the present application have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the application, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the application.
SEQUENCE LISTING
<110> Bozhen Biotechnology (Hangzhou) Co., ltd
<120> recombinant protein and use thereof
<130> PDI210493
<160> 34
<170> PatentIn version 3.5
<210> 1
<211> 57
<212> DNA
<213> Artificial Sequence
<220>
<223> 1
<400> 1
aaggactgga gtataagcgc ccgatactcc gcagtataca gtatccatcc ctcatgg 57
<210> 2
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> 2
<400> 2
gcagttccaa tgacctatcg cgccgca 27
<210> 3
<211> 45
<212> DNA
<213> Artificial Sequence
<220>
<223> 3
<400> 3
tacgccagct accactgctg gtgctggagg gaccccggca ggagc 45
<210> 4
<211> 31
<212> DNA
<213> Artificial Sequence
<220>
<223> 4
<400> 4
gtctccgtga gccacttcca gaaggtgtgg g 31
<210> 5
<211> 117
<212> DNA
<213> Artificial Sequence
<220>
<223> 5
<400> 5
gcagcctggg ggcaggccat attggaaggc gagcttgcat ggctggaggg cgggggcggc 60
ggtgctggcc aactggccga cctgaaacgg cagcttgctt ggtggaagca agctgca 117
<210> 6
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<223> 6
<400> 6
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
<210> 7
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> 7
<400> 7
tatccatacg acgtgccaga ttatgct 27
<210> 8
<211> 277
<212> DNA
<213> Artificial Sequence
<220>
<223> 8
<400> 8
aaggactgga gtataagcgc ccgatactcc gcagtataca gtatccatcc ctcatgggca 60
gttccaatga cctatcgcgc cgcatacgcc agctaccact gctggtgctg gagggacccc 120
ggcaggagcg tctccgtgag ccacttccag aaggtgtggg gcagcctggg ggcaggccat 180
attggaaggc gagcttgcat ggctggaggg cgggggcggc ggtgctggcc aactggccga 240
cctgaaacgg cagcttgctt ggtggaagca agctgca 277
<210> 9
<211> 277
<212> DNA
<213> Artificial Sequence
<220>
<223> 9
<400> 9
tacgccagct accactgctg gtgctggagg gaccccggca ggagcgcagc ctgggggcag 60
gccatattgg aaggcgagct tgcatggctg gagggcgggg gcggcggtgc tggccaactg 120
gccgacctga aacggcagct tgcttggtgg aagcaagctg caaaggactg gagtataagc 180
gcccgatact ccgcagtata cagtatccat ccctcatggg cagttccaat gacctatcgc 240
gccgcagtct ccgtgagcca cttccagaag gtgtggg 277
<210> 10
<211> 232
<212> DNA
<213> Artificial Sequence
<220>
<223> 10
<400> 10
gtctccgtga gccacttcca gaaggtgtgg gaaggactgg agtataagcg cccgatactc 60
cgcagtatac agtatccatc cctcatgggc agcctggggg caggccatat tggaaggcga 120
gcttgcatgg ctggagggcg ggggcggcgg tgctggccaa ctggccgacc tgaaacggca 180
gcttgcttgg tggaagcaag ctgcagcagt tccaatgacc tatcgcgccg ca 232
<210> 11
<211> 277
<212> DNA
<213> Artificial Sequence
<220>
<223> 11
<400> 11
tacgccagct accactgctg gtgctggagg gaccccggca ggagcaagga ctggagtata 60
agcgcccgat actccgcagt atacagtatc catccctcat gggcagcctg ggggcaggcc 120
atattggaag gcgagcttgc atggctggag ggcgggggcg gcggtgctgg ccaactggcc 180
gacctgaaac ggcagcttgc ttggtggaag caagctgcag tctccgtgag ccacttccag 240
aaggtgtggg gcagttccaa tgacctatcg cgccgca 277
<210> 12
<211> 277
<212> DNA
<213> Artificial Sequence
<220>
<223> 12
<400> 12
gcagttccaa tgacctatcg cgccgcatac gccagctacc actgctggtg ctggagggac 60
cccggcagga gcgcagcctg ggggcaggcc atattggaag gcgagcttgc atggctggag 120
ggcgggggcg gcggtgctgg ccaactggcc gacctgaaac ggcagcttgc ttggtggaag 180
caagctgcaa aggactggag tataagcgcc cgatactccg cagtatacag tatccatccc 240
tcatgggtct ccgtgagcca cttccagaag gtgtggg 277
<210> 13
<211> 144
<212> DNA
<213> Artificial Sequence
<220>
<223> 13
<400> 13
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
aaggactgga gtataagcgc ccgatactcc gcagtataca gtatccatcc ctcatggtat 120
ccatacgacg tgccagatta tgct 144
<210> 14
<211> 114
<212> DNA
<213> Artificial Sequence
<220>
<223> 14
<400> 14
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
gcagttccaa tgacctatcg cgccgcatat ccatacgacg tgccagatta tgct 114
<210> 15
<211> 132
<212> DNA
<213> Artificial Sequence
<220>
<223> 15
<400> 15
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
tacgccagct accactgctg gtgctggagg gaccccggca ggagctatcc atacgacgtg 120
ccagattatg ct 132
<210> 16
<211> 118
<212> DNA
<213> Artificial Sequence
<220>
<223> 16
<400> 16
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
gtctccgtga gccacttcca gaaggtgtgg gtatccatac gacgtgccag attatgct 118
<210> 17
<211> 204
<212> DNA
<213> Artificial Sequence
<220>
<223> 17
<400> 17
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
gcagcctggg ggcaggccat attggaaggc gagcttgcat ggctggaggg cgggggcggc 120
ggtgctggcc aactggccga cctgaaacgg cagcttgctt ggtggaagca agctgcatat 180
ccatacgacg tgccagatta tgct 204
<210> 18
<211> 364
<212> DNA
<213> Artificial Sequence
<220>
<223> 18
<400> 18
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
aaggactgga gtataagcgc ccgatactcc gcagtataca gtatccatcc ctcatgggca 120
gttccaatga cctatcgcgc cgcatacgcc agctaccact gctggtgctg gagggacccc 180
ggcaggagcg tctccgtgag ccacttccag aaggtgtggg gcagcctggg ggcaggccat 240
attggaaggc gagcttgcat ggctggaggg cgggggcggc ggtgctggcc aactggccga 300
cctgaaacgg cagcttgctt ggtggaagca agctgcatat ccatacgacg tgccagatta 360
tgct 364
<210> 19
<211> 364
<212> DNA
<213> Artificial Sequence
<220>
<223> 19
<400> 19
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
tacgccagct accactgctg gtgctggagg gaccccggca ggagcgcagc ctgggggcag 120
gccatattgg aaggcgagct tgcatggctg gagggcgggg gcggcggtgc tggccaactg 180
gccgacctga aacggcagct tgcttggtgg aagcaagctg caaaggactg gagtataagc 240
gcccgatact ccgcagtata cagtatccat ccctcatggg cagttccaat gacctatcgc 300
gccgcagtct ccgtgagcca cttccagaag gtgtgggtat ccatacgacg tgccagatta 360
tgct 364
<210> 20
<211> 319
<212> DNA
<213> Artificial Sequence
<220>
<223> 20
<400> 20
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
gtctccgtga gccacttcca gaaggtgtgg gaaggactgg agtataagcg cccgatactc 120
cgcagtatac agtatccatc cctcatgggc agcctggggg caggccatat tggaaggcga 180
gcttgcatgg ctggagggcg ggggcggcgg tgctggccaa ctggccgacc tgaaacggca 240
gcttgcttgg tggaagcaag ctgcagcagt tccaatgacc tatcgcgccg catatccata 300
cgacgtgcca gattatgct 319
<210> 21
<211> 364
<212> DNA
<213> Artificial Sequence
<220>
<223> 21
<400> 21
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
tacgccagct accactgctg gtgctggagg gaccccggca ggagcaagga ctggagtata 120
agcgcccgat actccgcagt atacagtatc catccctcat gggcagcctg ggggcaggcc 180
atattggaag gcgagcttgc atggctggag ggcgggggcg gcggtgctgg ccaactggcc 240
gacctgaaac ggcagcttgc ttggtggaag caagctgcag tctccgtgag ccacttccag 300
aaggtgtggg gcagttccaa tgacctatcg cgccgcatat ccatacgacg tgccagatta 360
tgct 364
<210> 22
<211> 364
<212> DNA
<213> Artificial Sequence
<220>
<223> 22
<400> 22
atgtacagga tgcagctcct gtcttgcatt gcactgagtc tggcactcgt cacaaacagc 60
gcagttccaa tgacctatcg cgccgcatac gccagctacc actgctggtg ctggagggac 120
cccggcagga gcgcagcctg ggggcaggcc atattggaag gcgagcttgc atggctggag 180
ggcgggggcg gcggtgctgg ccaactggcc gacctgaaac ggcagcttgc ttggtggaag 240
caagctgcaa aggactggag tataagcgcc cgatactccg cagtatacag tatccatccc 300
tcatgggtct ccgtgagcca cttccagaag gtgtgggtat ccatacgacg tgccagatta 360
tgct 364
<210> 23
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> 23
<400> 23
Lys Asp Trp Ser Ile Ser Ala Arg Tyr Ser Ala Val Tyr Ser Ile His
1 5 10 15
Pro Ser Trp
<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> 24
<400> 24
Ala Val Pro Met Thr Tyr Arg Ala Ala
1 5
<210> 25
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> 25
<400> 25
Tyr Ala Ser Tyr His Cys Trp Cys Trp Arg Asp Pro Gly Arg Ser
1 5 10 15
<210> 26
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> 26
<400> 26
Val Ser Val Ser His Phe Gln Lys Val Trp Val Val
1 5 10
<210> 27
<211> 39
<212> PRT
<213> Artificial Sequence
<220>
<223> 27
<400> 27
Ala Ala Trp Gly Gln Ala Ile Leu Glu Gly Glu Leu Ala Trp Leu Glu
1 5 10 15
Gly Gly Gly Gly Gly Ala Gly Gln Leu Ala Asp Leu Lys Arg Gln Leu
20 25 30
Ala Trp Trp Lys Gln Ala Ala
35
<210> 28
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> 28
<400> 28
Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu
1 5 10 15
Val Thr Asn Ser
20
<210> 29
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> 29
<400> 29
Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
1 5
<210> 30
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> 30
<400> 30
Tyr Ala Ser Tyr His Cys Trp Cys Trp Arg Asp Pro Gly Arg Ser Ala
1 5 10 15
Ala Trp Gly Gln Ala Ile Leu Glu Gly Glu Leu Ala Trp Leu Glu Gly
20 25 30
Gly Gly Gly Gly Ala Gly Gln Leu Ala Asp Leu Lys Arg Gln Leu Ala
35 40 45
Trp Trp Lys Gln Ala Ala Lys Asp Trp Ser Ile Ser Ala Arg Tyr Ser
50 55 60
Ala Val Tyr Ser Ile His Pro Ser Trp Ala Val Pro Met Thr Tyr Arg
65 70 75 80
Ala Ala Val Ser Val Ser His Phe Gln Lys Val Trp Val Val
85 90
<210> 31
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> 31
<400> 31
Val Ser Val Ser His Phe Gln Lys Val Trp Val Val Lys Asp Trp Ser
1 5 10 15
Ile Ser Ala Arg Tyr Ser Ala Val Tyr Ser Ile His Pro Ser Trp Tyr
20 25 30
Ala Ser Tyr His Cys Trp Cys Trp Arg Asp Pro Gly Arg Ser Ala Ala
35 40 45
Trp Gly Gln Ala Ile Leu Glu Gly Glu Leu Ala Trp Leu Glu Gly Gly
50 55 60
Gly Gly Gly Ala Gly Gln Leu Ala Asp Leu Lys Arg Gln Leu Ala Trp
65 70 75 80
Trp Lys Gln Ala Ala Ala Val Pro Met Thr Tyr Arg Ala Ala
85 90
<210> 32
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> 32
<400> 32
Tyr Ala Ser Tyr His Cys Trp Cys Trp Arg Asp Pro Gly Arg Ser Lys
1 5 10 15
Asp Trp Ser Ile Ser Ala Arg Tyr Ser Ala Val Tyr Ser Ile His Pro
20 25 30
Ser Trp Ala Ala Trp Gly Gln Ala Ile Leu Glu Gly Glu Leu Ala Trp
35 40 45
Leu Glu Gly Gly Gly Gly Gly Ala Gly Gln Leu Ala Asp Leu Lys Arg
50 55 60
Gln Leu Ala Trp Trp Lys Gln Ala Ala Val Ser Val Ser His Phe Gln
65 70 75 80
Lys Val Trp Val Val Ala Val Pro Met Thr Tyr Arg Ala Ala
85 90
<210> 33
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> 33
<400> 33
Ala Val Pro Met Thr Tyr Arg Ala Ala Tyr Ala Ser Tyr His Cys Trp
1 5 10 15
Cys Trp Arg Asp Pro Gly Arg Ser Ala Ala Trp Gly Gln Ala Ile Leu
20 25 30
Glu Gly Glu Leu Ala Trp Leu Glu Gly Gly Gly Gly Gly Ala Gly Gln
35 40 45
Leu Ala Asp Leu Lys Arg Gln Leu Ala Trp Trp Lys Gln Ala Ala Lys
50 55 60
Asp Trp Ser Ile Ser Ala Arg Tyr Ser Ala Val Tyr Ser Ile His Pro
65 70 75 80
Ser Trp Val Ser Val Ser His Phe Gln Lys Val Trp Val Val
85 90
<210> 34
<211> 94
<212> PRT
<213> Artificial Sequence
<220>
<223> 34
<400> 34
Lys Asp Trp Ser Ile Ser Ala Arg Tyr Ser Ala Val Tyr Ser Ile His
1 5 10 15
Pro Ser Trp Ala Val Pro Met Thr Tyr Arg Ala Ala Tyr Ala Ser Tyr
20 25 30
His Cys Trp Cys Trp Arg Asp Pro Gly Arg Ser Val Ser Val Ser His
35 40 45
Phe Gln Lys Val Trp Val Val Ala Ala Trp Gly Gln Ala Ile Leu Glu
50 55 60
Gly Glu Leu Ala Trp Leu Glu Gly Gly Gly Gly Gly Ala Gly Gln Leu
65 70 75 80
Ala Asp Leu Lys Arg Gln Leu Ala Trp Trp Lys Gln Ala Ala
85 90
Claims (14)
1. A recombinant protein comprising at least two of the following:
d4-2, C25, TPP-1, PPL-C and ERY2-4.
2. The recombinant protein according to claim 1, including D4-2, C25, TPP-1, PPL-C and ERY2-4.
3. The recombinant protein according to claim 2, wherein said D4-2C-terminus is linked to said C25N-terminus, said C25C-terminus is linked to said TPP-1N-terminus, said TPP-1C-terminus is linked to said PPL-C N-terminus, and said PPL-C-terminus is linked to said ERY 2-4N-terminus.
4. The recombinant protein according to claim 1, wherein said recombinant protein has an amino acid sequence as shown in SEQ ID No. 30, or an amino acid sequence having at least 95%, 90%, 85% identity with the amino acid sequence as shown in SEQ ID No. 25.
5. A nucleic acid encoding the recombinant protein of any one of claims 1-4.
6. The nucleic acid of claim 5, wherein the nucleic acid has the sequence of SEQ ID NO:8, and a nucleotide sequence shown in SEQ ID NO.
7. An expression vector comprising the nucleic acid of claim 5 or 6.
8. A method for preparing the recombinant protein according to any one of claims 1 to 4, comprising:
introducing the expression vector of claim 7 into a recipient cell;
the recipient cells carrying the expression vector are cultured under conditions suitable for the expression and secretion of the protein, so as to obtain the recombinant protein.
9. The method of claim 8, wherein the recipient cell comprises a eukaryotic cell;
optionally, the eukaryotic cell comprises a mammalian cell,
optionally, the mammalian cells comprise at least one selected from the group consisting of T cells, CHO-K1, CHOs, 293F, 293T, CAR-T, TCR-T, TIL, CAR-NK, CAR-M, and CAR-DC.
10. A recombinant cell carrying the nucleic acid of claim 5 or 6, the expression vector of claim 7 or the recombinant protein of any one of claims 1-4.
11. An immune effector cell carrying the nucleic acid of claim 5 or 6, the expression vector of claim 7, or the recombinant protein of any one of claims 1-4;
optionally, the immune effector cell is a T cell, preferably CD8 + T cells.
12. A composition, comprising:
the recombinant protein of any one of claims 1-4, the nucleic acid of claim 5 or 6, the expression vector of claim 7, the recombinant cell of claim 10, or the immune effector cell of claim 11.
13. Use of the recombinant protein of any one of claims 1-4, the nucleic acid of claim 5 or 6, the expression vector of claim 7, the recombinant cell of claim 10, the immune effector cell of claim 11, or the composition of claim 12 in the manufacture of a medicament for treating or preventing cancer;
optionally, the cancer comprises at least one selected from the group consisting of: gastric cancer, intestinal cancer, head and neck cancer and melanoma.
14. A medicament, comprising: the recombinant protein of any one of claims 1-4, the nucleic acid of claim 5 or 6, the expression vector of claim 7, the recombinant cell of claim 10, the immune effector cell of claim 11, or the composition of claim 12, for use in the treatment or prevention of cancer;
optionally, the cancer comprises at least one selected from the group consisting of: gastric cancer, intestinal cancer, head and neck cancer and melanoma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210193357.0A CN116731193A (en) | 2022-03-01 | 2022-03-01 | Recombinant proteins and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210193357.0A CN116731193A (en) | 2022-03-01 | 2022-03-01 | Recombinant proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116731193A true CN116731193A (en) | 2023-09-12 |
Family
ID=87915555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210193357.0A Pending CN116731193A (en) | 2022-03-01 | 2022-03-01 | Recombinant proteins and uses thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116731193A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2333074A1 (en) * | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
CN108503691A (en) * | 2017-02-25 | 2018-09-07 | 复旦大学 | A kind of human PD-L 1 albumen high-affinity peptide and its application |
CN111840585A (en) * | 2020-07-20 | 2020-10-30 | 厦门大学 | Pharmaceutical composition for tumor immunotherapy |
CN113993553A (en) * | 2019-04-08 | 2022-01-28 | 费城儿童医院 | Treatment of lysosomal storage diseases of the eye by administration of an AAV expressing TPP1 |
-
2022
- 2022-03-01 CN CN202210193357.0A patent/CN116731193A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2333074A1 (en) * | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
CN108503691A (en) * | 2017-02-25 | 2018-09-07 | 复旦大学 | A kind of human PD-L 1 albumen high-affinity peptide and its application |
CN113993553A (en) * | 2019-04-08 | 2022-01-28 | 费城儿童医院 | Treatment of lysosomal storage diseases of the eye by administration of an AAV expressing TPP1 |
CN111840585A (en) * | 2020-07-20 | 2020-10-30 | 厦门大学 | Pharmaceutical composition for tumor immunotherapy |
Non-Patent Citations (5)
Title |
---|
FURUKAWA等: "Peptides that immunoactivate the tumor microenvironment", 《BBA-REVIEWS ON CANCER》, pages 188486 * |
MUDIYANSELAGE等: "An Immune-Stimulatory Helix-Loop-Helix Peptide: Selective Inhibition of CTLA-4-B7 Interaction", 《ACS CHEMICAL BIOLOGY》, pages 360 - 368 * |
SASIKUMAR等: "Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy", 《MEDICINE IN DRUG DISCOVERY》, pages 100073 * |
UNIPROT: "PLCE1_HUMAN", 《UNIPROT》, pages 9 * |
孟祥州: "多肽药物筛选及基于肿瘤细胞膜的多肽运载体系的构建与应用", 《中国学位论文全文数据库》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113913379B (en) | T lymphocyte and application thereof | |
CN113164519A (en) | Genetically modified tetra-cistronic system comprising a homing receptor or cytokine and a chimeric antigen receptor for immunotherapy | |
CN111363046A (en) | Chimeric antigen receptor targeting NKG2D, chimeric antigen receptor T cell, and preparation method and application thereof | |
CN108070607A (en) | Target Chimeric antigen receptor of CD19-41BB-tEGFR and application thereof | |
CN111205361B (en) | Interleukin 21 protein (IL21) mutant and application thereof | |
EP2995626B1 (en) | Bifunctional fusion proteins to inhibit angiogenesis in tumour microenvironment and to activate adaptive immune responses and the genes and uses thereof | |
CN113896801B (en) | Chimeric antigen receptor cell targeting human Claudin18.2 and NKG2DL, and preparation method and application thereof | |
CN113773402B (en) | Double-target chimeric antigen receptor, nucleic acid molecule, vector, cell and pharmaceutical composition | |
CN109836496A (en) | It is a kind of to target the single-chain antibody of CD317, Chimeric antigen receptor T cell and its preparation method and application | |
CN113248625B (en) | Fusion protein, gene encoding fusion protein, recombinant vector and application of fusion protein and gene | |
CN113583139A (en) | Chimeric receptor and application thereof | |
CN113416260B (en) | Claudin18.2-targeted specific chimeric antigen receptor cell and preparation method and application thereof | |
CN109265565B (en) | anti-CD 79b chimeric antigen receptor carrying molecular switch, immune cell modified by same and application of immune cell | |
CN109836495A (en) | It is a kind of to target the single-chain antibody of CD22, Chimeric antigen receptor T cell and its preparation method and application | |
CN109836497A (en) | A kind of single-chain antibody of targeting EGFR, Chimeric antigen receptor T cell and its preparation method and application | |
WO2021074695A1 (en) | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. | |
WO2017071173A1 (en) | Tumor therapeutic agent modified by il-12/cd62l fusion protein and preparation method and use thereof | |
CN110526970A (en) | Target single-chain antibody, the Chimeric antigen receptor T cell and its preparation method and application of CD133 | |
CN116179495A (en) | Transgenic immune cells and uses thereof | |
CN109836493A (en) | It is a kind of to target the single-chain antibody of CD19, Chimeric antigen receptor T cell and its preparation method and application | |
CN110157676A (en) | A kind of targeting T lymphocyte and its preparation method and application | |
CN111632135A (en) | Application of chimeric antigen receptor T cell targeting NKG2D in treatment of prostate cancer and medicine for treating prostate cancer | |
CN109957018A (en) | It is a kind of to target the single-chain antibody of CD22, Chimeric antigen receptor T cell and its preparation method and application | |
CN111499766B (en) | Immune effector cell aiming at chronic lymphocytic leukemia, preparation method and application thereof | |
CN110157677A (en) | A kind of targeting T lymphocyte and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |